Scholarlink

Purpose <p>Sarcopenia and frailty are major determinants of morbidity and mortality in cirrhosis. Transjugular intrahepatic portosystemic shunt (TIPS) creation for refractory ascites may reverse muscle loss, but prospective evidence is lacking.</p> Materials and Methods <p>In this single-center pilot randomized controlled trial, 26 cirrhotic adults with non-emergent complications of portal hypertension were allocated to standard of care (SOC) or SOC + TIPS creation. Fourteen completed six-month follow-up. Primary outcomes were the CT-derived skeletal (SMI) and psoas (PMI) muscle indices, adiposity, Short Physical Performance Battery, and Liver Frailty Index at baseline and at 6&#xa0;months. Secondary outcomes included quality of life (QOL), MELD score, adverse events, and survival.</p> Results <p>In the TIPS cohort, SMI and PMI increased significantly (both <i>p</i> &lt; 0.05), along with increases in multiple adiposity indices (<i>p</i> &lt; 0.05). In contrast, no body composition metrics showed significant changes in the SOC cohort. Between cohorts, the TIPS group showed significantly greater improvements in PMI (<i>p</i> &lt; 0.05), subcutaneous adipose tissue index (<i>p</i> &lt; 0.01), and intermuscular fat (<i>p</i> &lt; 0.05). A ≥ 10% SMI rise occurred in 71% (5/7, TIPS) versus 14% (1/7, SOC) of patients. All functional scores improved in the TIPS cohort (<i>p</i> &lt; 0.05), with no significant changes in the SOC cohort and significant between-cohort differences (<i>p</i> &lt; 0.05). There were no differences between cohorts in hepatic encephalopathy, MELD scores, or survival (<i>p</i> &gt; 0.05).</p> Conclusion <p>In this pilot randomized trial, TIPS creation appeared to improve body composition, physical function, and QOL in cirrhotic patients without increasing adverse events. Larger trials are needed to confirm its effects on sarcopenia and frailty.</p> Level of Evidence <p>Level 1, Randomized Controlled Trial.</p> Clinical Trial Registration <p>ClinicalTrials.gov (NCT05420753).</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Elective Transjugular Intrahepatic Portosystemic Shunt Creation in Cirrhosis Improves Body Composition and Function: Pilot Randomized Trial

  • 期刊论文

  • 发表日期：

    2026年3月10日

查看全文
  • Takeshi Suzuki,
  • Kentaro Yamada,
  • Arianna Anoushiravani,
  • Peter Pham,
  • Aaron J. Grossberg,
  • Willscott E. Naugler,
  • Khashayar Farsad

摘要

Purpose

Sarcopenia and frailty are major determinants of morbidity and mortality in cirrhosis. Transjugular intrahepatic portosystemic shunt (TIPS) creation for refractory ascites may reverse muscle loss, but prospective evidence is lacking.

Materials and Methods

In this single-center pilot randomized controlled trial, 26 cirrhotic adults with non-emergent complications of portal hypertension were allocated to standard of care (SOC) or SOC + TIPS creation. Fourteen completed six-month follow-up. Primary outcomes were the CT-derived skeletal (SMI) and psoas (PMI) muscle indices, adiposity, Short Physical Performance Battery, and Liver Frailty Index at baseline and at 6 months. Secondary outcomes included quality of life (QOL), MELD score, adverse events, and survival.

Results

In the TIPS cohort, SMI and PMI increased significantly (both p < 0.05), along with increases in multiple adiposity indices (p < 0.05). In contrast, no body composition metrics showed significant changes in the SOC cohort. Between cohorts, the TIPS group showed significantly greater improvements in PMI (p < 0.05), subcutaneous adipose tissue index (p < 0.01), and intermuscular fat (p < 0.05). A ≥ 10% SMI rise occurred in 71% (5/7, TIPS) versus 14% (1/7, SOC) of patients. All functional scores improved in the TIPS cohort (p < 0.05), with no significant changes in the SOC cohort and significant between-cohort differences (p < 0.05). There were no differences between cohorts in hepatic encephalopathy, MELD scores, or survival (p > 0.05).

Conclusion

In this pilot randomized trial, TIPS creation appeared to improve body composition, physical function, and QOL in cirrhotic patients without increasing adverse events. Larger trials are needed to confirm its effects on sarcopenia and frailty.

Level of Evidence

Level 1, Randomized Controlled Trial.

Clinical Trial Registration

ClinicalTrials.gov (NCT05420753).

Graphical Abstract